These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 30887650)
1. What is new in lipid-lowering therapies in diabetes? Cheung YM; O'Brien R; Ekinci EI Intern Med J; 2019 Dec; 49(12):1472-1480. PubMed ID: 30887650 [TBL] [Abstract][Full Text] [Related]
2. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404 [TBL] [Abstract][Full Text] [Related]
3. Lipid Management in Diabetes with a Focus on Emerging Therapies. Hoe E; Hegele RA Can J Diabetes; 2015 Dec; 39 Suppl 5():S183-90. PubMed ID: 26653256 [TBL] [Abstract][Full Text] [Related]
4. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Kim K; Ginsberg HN; Choi SH Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170 [TBL] [Abstract][Full Text] [Related]
5. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
7. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464 [TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
9. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk? Reklou A; Katsiki N; Karagiannis A; Athyros V Curr Vasc Pharmacol; 2020; 18(1):38-42. PubMed ID: 30663570 [TBL] [Abstract][Full Text] [Related]
10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum A; Fisman EZ; Motro M; Adler Y Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960 [TBL] [Abstract][Full Text] [Related]
11. Future perspectives of the pharmacological management of diabetic dyslipidemia. Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763 [TBL] [Abstract][Full Text] [Related]
12. An updated review of lipid-modifying therapy. Simons LA Med J Aust; 2019 Jul; 211(2):87-92. PubMed ID: 31006138 [TBL] [Abstract][Full Text] [Related]
13. Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. Lan NSR; Burns K; Bell DA; Watts GF Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):104-113. PubMed ID: 33278128 [TBL] [Abstract][Full Text] [Related]
14. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
15. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
16. Managing dyslipidemia in patients with Type 2 diabetes. Tomlinson B; Patil NG; Fok M; Lam CWK Expert Opin Pharmacother; 2021 Nov; 22(16):2221-2234. PubMed ID: 33823719 [TBL] [Abstract][Full Text] [Related]
17. Dyslipidemia in diabetes. Kalra S; Raizada N Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S80-S82. PubMed ID: 37956957 [TBL] [Abstract][Full Text] [Related]